<table id="tablei" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table I. Mean and range of total body clearance and half-life of theophylline related to age and altered physiological states.<footnote id="table1a">For various North American patient populations from literature reports. Different rates of elimination and consequent dosage requirements have been observed among other peoples.</footnote>
</caption>
<col align="left" valign="top" width="45%"></col>
<col align="left" valign="top" width="28%"></col>
<col align="left" valign="top" width="27%"></col>
<thead>
<tr>
<th valign="bottom">Population characteristics</th>
<th>Total body clearance<footnote id="table1b">Clearance represents the volume of blood completely cleared of theophylline by the liver in one minute. Values listed were generally determined at serum theophylline concentrations &lt;20 mcg/mL; clearance may decrease and half-life may increase at higher serum concentrations due to non-linear  pharmacokinetics.</footnote>
<br/>mean (range)<footnote id="table1c">Reported range or estimated range (mean Â±2 SD) where actual range not reported.</footnote>
<br/>(mL/kg/min)</th>
<th>Half-life <br/>mean (range)<footnoteref idref="table1c"></footnoteref>
<br/>(hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<content stylecode="bold underline">Age</content>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<content stylecode="underline">Premature neonates</content>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td>postnatal age 3-15 days</td>
<td>0.29 (0.09-0.49)</td>
<td>30 (17-43)</td>
</tr>
<tr>
<td>postnatal age 25-57 days</td>
<td>0.64 (0.04-1.2)</td>
<td>20 (9.4-30.6)</td>
</tr>
<tr>
<td>
<content stylecode="underline">Term infants</content>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td>postnatal age 1-2 days</td>
<td>NR<footnote id="table1d">NR = not reported or not reported in a comparable format. </footnote>
</td>
<td>25.7 (25-26.5)</td>
</tr>
<tr>
<td>postnatal age 3-30 weeks</td>
<td>NR<footnoteref idref="table1d"></footnoteref>
</td>
<td>11 (6-29)</td>
</tr>
<tr>
<td>
<content stylecode="underline">Children</content>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-4 years</td>
<td>1.7 (0.5-2.9)</td>
<td>3.4 (1.2-5.6)</td>
</tr>
<tr>
<td>4-12 years</td>
<td>1.6 (0.8-2.4)</td>
<td>NR<footnoteref idref="table1d"></footnoteref>
</td>
</tr>
<tr>
<td>13-15 years</td>
<td>0.9 (0.48-1.3)</td>
<td>NR<footnoteref idref="table1d"></footnoteref>
</td>
</tr>
<tr>
<td>16-17 years</td>
<td>1.4 (0.2-2.6)</td>
<td>3.7 (1.5-5.9)</td>
</tr>
<tr>
<td>
<content stylecode="underline">Adults (16-60 years)</content>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td>otherwise healthy non-smoking asthmatics</td>
<td valign="bottom">0.65 (0.27-1.03)</td>
<td valign="bottom">8.7 (6.1-12.8)</td>
</tr>
<tr>
<td>
<content stylecode="underline">Elderly (&gt;60 years)</content>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td>non-smokers with normal cardiac, liver, and renal function</td>
<td valign="bottom">0.41 (0.21-0.61)</td>
<td valign="bottom">9.8 (1.6-18)</td>
</tr>
<tr>
<td>
<content stylecode="bold underline">Concurrent illness or altered physiological state</content>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td rowspan="2">Acute pulmonary edema COPD - &gt;60 years, stable non-smoker &gt;1 year</td>
<td>0.33<footnote id="table1e">Median</footnote> (0.07-2.45)</td>
<td>19<footnoteref idref="table1e"></footnoteref> (3.1-82)</td>
</tr>
<tr>
<td valign="bottom">0.54 (0.44-0.64)</td>
<td valign="bottom">11 (9.4-12.6)</td>
</tr>
<tr>
<td>COPD with cor pulmonale<br/>Cystic fibrosis (14-28 years)</td>
<td>0.48 (0.08-0.88)<br/>1.25 (0.31-2.2)</td>
<td>NR<footnoteref idref="table1d"></footnoteref>
<br/>6.0 (1.8-10.2)</td>
</tr>
<tr>
<td>Fever associated with acute viral respiratory illness (children 9-15 years)</td>
<td valign="bottom">NR<footnoteref idref="table1d"></footnoteref>
</td>
<td valign="bottom">7.0 (1.0-13)</td>
</tr>
<tr>
<td>Liver disease - cirrhosis</td>
<td>0.31<footnoteref idref="table1e"></footnoteref> (0.1-0.7)</td>
<td>32<footnoteref idref="table1e"></footnoteref> (10-56) </td>
</tr>
<tr>
<td>acute hepatitis</td>
<td>0.35 (0.25-0.45)</td>
<td>19.2 (16.6-21.8)</td>
</tr>
<tr>
<td>cholestasis</td>
<td>0.65 (0.25-1.45)</td>
<td>14.4 (5.7-31.8)</td>
</tr>
<tr>
<td>Pregnancy - 1st trimester</td>
<td>NR<footnoteref idref="table1d"></footnoteref>
</td>
<td>8.5 (3.1-13.9)</td>
</tr>
<tr>
<td>2nd trimester</td>
<td>NR<footnoteref idref="table1d"></footnoteref>
</td>
<td>8.8-3.8-13.8</td>
</tr>
<tr>
<td>3rd trimester</td>
<td>NR<footnoteref idref="table1d"></footnoteref>
</td>
<td>13.0 (8.4-17.6)</td>
</tr>
<tr>
<td>Sepsis with multi-organ failure</td>
<td>0.47 (0.19-1.9)</td>
<td>18.8 (6.3-24.1)</td>
</tr>
<tr>
<td>Thyroid disease - hypothyroid</td>
<td>0.38 (0.13-0.57)</td>
<td>11.6 (8.2-25)</td>
</tr>
<tr>
<td>hyperthyroid</td>
<td>0.8 (0.68-0.97)</td>
<td>4.5 (3.7-5.6)</td>
</tr>
</tbody>
</table>